Study summary
An EZH1/2 inhibitor shrank tumors in 44% of people with relapsed disease
44%response rate
What was tested
Valemetostat, a pill that blocks the EZH1 and EZH2 enzymes controlling gene activity in lymphoma cells, for relapsed or refractory peripheral T-cell lymphoma.
What they found
- 44% of 119 evaluable people responded.
- Low platelets were the most common serious side effect.
What it means
Approved in Japan; one of several epigenetic drugs that work well in T-cell lymphomas.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.